A diagnosis and treatment integrated nanoprobe and its preparation method and application
By designing a nanoprobe Au-Mn2(CO)10@BSA-N3, combining CDT and gas therapy, using multiple ROS and Mn2+ catalytic reactions, the efficient treatment of bone metastasis in breast cancer is achieved, and the treatment in the prior art is solved The problem of limited effect has achieved the dual effects of tumor cell killing and osteoblast differentiation.
Patent Information
- Application Number
- CN202310163601.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-24
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-02-24
AI Technical Summary
Prior art Chemokinetic therapy (CDT) and gas therapy are limited and unsustainable in the treatment of bone metastasis in breast cancer, making it difficult to achieve efficient tumor cell killing and osteoblast differentiation.
Develop an integrated diagnosis and treatment nanoprobe Au-Mn2(CO)10@BSA-N3 (AM@BSAN), to achieve efficient CDT and gas synergistic treatment through multiple ROS enhancement within the tumor, and use Mn2+ catalytic reaction to produce high toxicity·OH. And promote H2O2 generation through Au nanoclusters, and combine with the gas delivery system to achieve local CO release to promote osteoblast differentiation.
It has achieved efficient killing of tumor cells and promoting osteoblast differentiation in tumor sites, improved the therapeutic effect through multiple ROS and gas synergistic treatment strategies, and enhanced the depth and persistence of treatment through NIR-II imaging and starvation treatment.
Smart Images

Figure CN116173245B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical nanomaterials, and in particular to a diagnosis and treatment integrated nanoprobe and a preparation method and application thereof. Background Art
[0002] In recent years, the incidence and mortality of cancer are increasing rapidly. Breast cancer, as an important public health issue, is the second leading cause of death among women. Bones are the most common site of metastasis of advanced breast cancer. Up to 75% of breast cancer patients often have bone metastases. Severe skeletal-related events (SREs) caused by bone metastases have a decisive impact on the life expectancy of breast cancer patients. Osteoblast inhibition and osteoclast differentiation induced by metastatic breast cancer cells are key initiators of bone metastasis and osteolytic bone lesions. Therefore, it may be beneficial to develop a fluorescent probe that simultaneously inhibits cancer cell invasion, promotes osteoblast differentiation, and can monitor the treatment process.
[0003] Reactive oxygen species (ROS), such as singlet oxygen, hydroxyl radicals (·OH), hydrogen peroxide (H2O2), etc., can effectively kill tumor cells by destroying intracellular DNA chains, proteins and other biological molecules. As an emerging treatment strategy, chemodynamic therapy (CDT) relies on the conversion of endogenous H2O2 in tumors into highly toxic ·OH through iron-based Fenton or Fenton-like reactions, thereby inducing intracellular oxidative stress and killing tumor cells. CDT not only overcomes the high toxicity of traditional tumor radiotherapy and chemotherapy, but also provides more alternative options for tumor treatment. In addition to several iron-based nanosystems reported as CDT agents, other transition metal compounds, including Mn 2+ 、Co 2+ and Cu 2+ , can also be used as a catalytic ion.
[0004] Gas therapy, as another emerging field, has attracted increasing attention due to its significant role in disease treatment. Common gas therapies include NO, CO, and H2S, but the effectiveness and biological effects of gas therapy largely depend on the concentration and duration of the treatment site. Endogenous CO generated by the body's heme enzyme metabolism is an important physiological gas transmitter that plays an important role in cell protection and regulation of cellular homeostasis in a variety of different tissues and cells. However, due to the strong affinity of CO to hemoglobin, it is also a silent killer, and uncontrollable CO release will have catastrophic consequences for the body. This has led to the efficient delivery of CO in the body receiving much attention. The vigorous development of nanomedicine in recent years has provided new ideas for new gas delivery methods. Nanomaterials usually have the function of targeted delivery at the tumor site, which can release carbon monoxide molecules (Mn2(CO) 10 ) is delivered to specific sites, while Mn2(CO)10 The in situ controlled release of CO can be triggered by H2O2 in the tumor microenvironment. However, the supply of H2O2 in the tumor microenvironment is often limited, making CO generation suboptimal. The high content of antioxidants inhibits ROS generation, making the above treatment strategy ideal but limited and unsustainable.
[0005] Therefore, it is urgent to develop a new nanoprobe that can enable the nanozyme to achieve efficient CDT and sustainable treatment strategies through coupling between nanozyme cascade catalytic reactions. Summary of the invention
[0006] In view of the above problems, the present invention provides a diagnosis and treatment integrated nanoprobe and its preparation method and application. The nanoprobe can achieve efficient CDT and gas synergistic therapy to kill tumor cells through starvation therapy and multiple ROS enhancement inside the tumor. At the same time, the release of local trace CO and Mn 2+ Helps in the differentiation of osteoblasts.
[0007] In order to achieve the above object, the present invention adopts the following technical solutions:
[0008] The present invention provides a diagnosis and treatment integrated nanoprobe, wherein the nanoprobe is Au-Mn2(CO) 10 @BSA-N3 (AM@BSAN), its structure is evenly distributed and its morphology is spherical;
[0009] The core of the nanoprobe spherical structure is a gold cluster loaded with carbon monoxide releasing molecules Mn2(CO) 10 The composite structure formed uses reduced glutathione as a ligand, and is coated with bovine serum albumin and modified with azide compounds. The large number of carboxyl groups contained in the core can interact with the Ca on the surface of hydroxyapatite, the main component of bone. 2+ Specific binding improves the affinity of the probe for bone tissue. External coating with bovine serum albumin can not only improve the biocompatibility of the probe but also increase the high permeability and retention effect (EPR effect) on tumors. The externally modified azide compound can specifically bind to macrophages, further enhancing its aggregation at the tumor site.
[0010] Furthermore, the hydrated particle size of the nanoprobe is about 10-13 nm.
[0011] The present invention also provides a method for preparing a diagnosis and treatment integrated nanoprobe, wherein the probe is based on a gold cluster and loaded with Mn2(CO) 10 The formed composite structure is used as the core of the nanocluster, and bovine serum albumin is coated on the outside of the nanocluster and modified with an azide compound.
[0012] Furthermore, the preparation method specifically comprises the following steps:
[0013] S1: adding tetrachloroauric acid trihydrate aqueous solution into deionized water, and then adding reduced glutathione aqueous solution under high-speed stirring to form a transparent aqueous solution of gold clusters protected by glutathione as a ligand;
[0014] S2: Mn2(CO) dissolved in dimethyl sulfoxide (DMSO) 10 Add the compound solution to the solution obtained in step S1 and continue stirring;
[0015] S3: adding the bovine serum albumin aqueous solution to the solution in step S2 under stirring to obtain a clear mixed solution;
[0016] S4: adjusting the pH of the solution in step S3 with an aqueous potassium hydroxide solution;
[0017] S5: CO2 is introduced into the solution obtained in step S4 and the stirring is continued, followed by washing, centrifugation, and freeze-drying to obtain a nanocomplex AM@BSA wrapped by bovine serum albumin;
[0018] S6: Mix and stir the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride aqueous solution (EDC), the N-hydroxysuccinimide aqueous solution (NHS) and the 3-azidopropylamine solution, add the aqueous solution of the nanocomplex AM@BSA obtained in step S5 and continue stirring, then centrifuge and wash the product to obtain the integrated diagnosis and treatment nanoprobe.
[0019] Furthermore, in step S1, the concentration of the tetrachloroauric acid trihydrate aqueous solution is 126-131.8 mg / mL, and the amount is 1 mL; the concentration of the reduced glutathione aqueous solution is 75.15-81.1 mg / mL, and the amount is 2-2.5 mL; the amount of water is 275.5-278 mL; the stirring speed is 880 r / min, and the stirring time is 8 min.
[0020] In step S2, Mn2(CO) 10 The concentration of the solution is 5-24.96 mg / mL, the dosage is 0.5 mL; the stirring speed is 880 r / min, and the stirring time is 8 min.
[0021] The concentration of the bovine serum albumin aqueous solution in step S3 is 31.5 mg / mL, the dosage is 2-4 mL, and the stirring time is 15 min.
[0022] The concentration of the potassium hydroxide aqueous solution in step S4 is 2 mol / L, and the adjusted pH value is 11.
[0023] In step S5, the CO ventilation pressure is 1 bar, and the ventilation time is 15 min; the stirring temperature of the reaction mixture is room temperature, and the stirring time is 24 h; the centrifugation uses an ultrafiltration separation tube 10KD, the speed is 3500 r / min, and the time is 10 min.
[0024] In the step S6, the concentration of the EDC aqueous solution is 1 mg / mL, and the dosage is 1.116 mL; the concentration of the NHS aqueous solution is 1 mg / mL, and the dosage is 0.99 mL; the concentration of the 3-azidopropylamine solution is 10 mg / mL, and the dosage is 2-3 mL; the stirring temperature is room temperature, and the stirring time is 60 min; the concentration of the nanocomposite AM@BSA aqueous solution is 2 mg / mL, and the dosage is 5 mL; the nanocomposite AM@BSA aqueous solution is added and the stirring condition is continued in an ice water bath for 12 hours; the centrifugal separation uses an ultrafiltration separation tube 30KD, the speed is 3500 r / min, and the time is 15 min.
[0025] The present invention also provides an application of an integrated diagnosis and treatment nanoprobe for preparing an integrated diagnosis and treatment nanoreagent for bone metastasis.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] The present invention discloses an integrated diagnosis and treatment nanoprobe, which has an EPR effect in the solid tumor area, and can respond and specifically release CO in the tumor microacid and H2O2 environment. CO, as a gas signal molecule, regulates mitochondrial respiration to cause ROS to increase; and the improvement of the therapeutic effect of CDT is achieved by simulating glutathione oxidase (GSHOD), through the production of Mn ions, and consuming the tumor's internal antioxidant system GSH. The Mn ions released by the nanoprobe can be reduced by the tumor's internal antioxidant system GSH, and while consuming antioxidants, it relies on the Mn-like Fenton reaction to produce highly toxic ·OH. The Au nanoclusters in the nanoprobe can play the role of NIR-II imaging. In addition, the glucose oxidase activity contained in Au can convert the excess glucose inside the tumor into H2O2, achieving starvation treatment of the tumor. At the same time, the glucose oxidase activity of the Au nanoclusters causes H2O2 to produce ·OH, which plays a cascade catalytic role in inducing intracellular oxidative stress. Through starvation treatment and multiple ROS increases inside the tumor, an efficient CDT and gas synergistic treatment strategy for killing tumor cells is achieved. At the same time, the release of local trace CO and Mn 2+ Helps in the differentiation of osteoblasts.
[0028] In addition, since the absorption spectrum of this material is in the near-infrared region II, it has a deeper penetration depth, which can achieve better imaging and treatment effects. At the same time, starvation therapy, chemodynamics and gas therapy can be used as auxiliary therapies to comprehensively improve the role of this material in all stages of tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is a transmission electron microscopy image of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0030] Figure 2 This is an analysis of the particle size and Zeta potential changes of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0031] Figure 3 This is the X-ray photoelectron energy spectrum of the Au element of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0032] Figure 4 This is the X-ray photoelectron spectrum of the Mn element of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0033] Figure 5 This is the OH generation capability of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0034] Figure 6 This is the CO release capability of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0035] Figure 7 The peroxidase activity of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention at different times.
[0036] Figure 8 This is a study on the cytotoxicity of CCK-8 of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0037] Fig. 9 This is the in vivo imaging image of the NIR-II integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention. Fig. 9 The upper part is a fluorescent in vivo imaging image of the experimental mouse in the supine position. It can be observed that the probe exhibits the greatest aggregation effect on the lesion site (left leg) at 8-10 hours; Fig. 9 The lower part is a fluorescent live imaging image of the experimental mouse after ex vivo testing, indicating that the nanoprobe is metabolized through the kidneys and has no aggregation in tissues such as the heart, liver, spleen, and lungs, while the aggregation of fluorescent signals can be detected in abnormal leg bones ex vivo. DETAILED DESCRIPTION
[0038] The technical solution of the present invention will be clearly and completely described below in combination with the embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] Example 1
[0040] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0041] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0042] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0043] Take 162 mg of reduced glutathione and 2 mL of deionized water, add them into an EP tube and place it in an ultrasonic disperser to fully dissolve and disperse, with a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0044] Take Mn2(CO) 10 12.48 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0045] Take 126 mg of bovine serum albumin and 4 mL of deionized water, fully dissolve to obtain a bovine serum albumin solution for use;
[0046] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0047] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0048] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0049] Take 276 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 100.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the solution color was still clear and transparent; 4 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the solution color remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution was observed to change from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0050] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0051] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 3 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0052] The prepared nanoprobe was dissolved in PBS buffer and injected into the rat tail vein to detect the imaging performance of the nanoprobe.
[0053] Figure 1 This is a transmission electron microscope image of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention. It can be seen from the figure that the nanoparticles of the synthesized integrated diagnosis and treatment nanoprobe are evenly distributed and have a spherical cluster structure.
[0054] Figure 2 This is an analysis of the particle size and Zeta potential change of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention. As can be seen from the figure, the final particle size of the synthesized nanoprobe is about 12nm, the size distribution is uniform (10-13nm), and the charge of the nanoprobe during the synthesis process is around -10mV.
[0055] Figure 3 This is the X-ray photoelectron spectrum of the Au element of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0056] Figure 4The integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention is an X-ray photoelectron spectrum of the Mn element.
[0057] Figure 5 The integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention generates ·OH. Tetramethylbenzidine (TMB) is used as a color substrate for peroxidase to simulate the detection of peroxidase activity of the nanoprobe AM@BSAN. Figure 5 It can be seen that in the presence of H2O2, the probe AM@BSAN can catalyze the decomposition of H2O2 to produce ·OH, and then ·OH oxidizes TMB to produce blue oxide with an absorption peak at 652nm.
[0058] Figure 6 This is the CO release capability of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention. As can be seen from the figure, the ultraviolet characteristic peaks of deoxyhemoglobin (430, 560nm) gradually change to the characteristic peaks of carboxyhemoglobin (410, 540, 578nm), indicating that the nanoprobe AM@BSAN of the present invention has the ability to release CO.
[0059] Figure 7 This is the peroxidase-like ability of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention.
[0060] Figure 8 This is a CCK-8 study of the cytotoxicity of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention on osteoblast precursor cells MC3T3-E1. As can be seen from the figure, different concentrations of AM@BSAN nanoprobes have no obvious effect on the proliferation inhibition rate of normal cells, showing low toxicity.
[0061] Fig. 9 This is the NIR-II in vivo imaging image of the integrated diagnosis and treatment nanoprobe synthesized in Example 1 of the present invention. As can be seen from the figure, after the tail vein administration, the fluorescence signal in the bone tissue gradually accumulated, and the drug concentration in the left tibia tumor modeling site was the highest at 8 hours, after which the drug was gradually metabolized, and the drug concentration in the tumor and other parts of the body decreased.
[0062] Based on the above results, it is shown that the nanoprobe of the present invention is an integrated nanoprobe for NIR-II diagnosis and treatment of bone metastasis that responds to the release of CO and synergistically inhibits gas and chemical kinetics.
[0063] Example 2
[0064] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0065] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0066] Take 131.8 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0067] Take 150.3 mg of reduced glutathione and 2 mL of deionized water, add them into an EP tube and place it in an ultrasonic disperser to fully dissolve and disperse, with a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0068] Take Mn2(CO) 10 2.5 mg of the compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use.
[0069] Take 126 mg of bovine serum albumin and 4 mL of deionized water, fully dissolve to obtain a bovine serum albumin solution for use;
[0070] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0071] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0072] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0073] Take 276 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the solution color was still clear and transparent; 4 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the solution color remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution was observed to change from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0074] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0075] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 3 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0076] Example 3
[0077] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0078] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0079] Take 128.9 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0080] Take 150.3 mg of reduced glutathione and 2 mL of deionized water, add them into an EP tube and place it in an ultrasonic disperser to fully dissolve and disperse, with a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0081] Take Mn2(CO) 10 2.5 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0082] Take 63 mg of bovine serum albumin and 2 mL of deionized water, and fully dissolve to obtain a bovine serum albumin solution for use;
[0083] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0084] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0085] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0086] Take 278 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the color of the solution remained clear and transparent; 2 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the color of the solution remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution changed from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0087] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0088] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0089] Example 4
[0090] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0091] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0092] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0093] Take 162 mg of reduced glutathione and 2 mL of deionized water, add them into an EP tube and place it in an ultrasonic disperser to fully dissolve and disperse, with a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0094] Take Mn2(CO) 10 12.48 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0095] Take 63 mg of bovine serum albumin and 2 mL of deionized water, and fully dissolve to obtain a bovine serum albumin solution for use;
[0096] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0097] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0098] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0099] Take 278 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the color of the solution remained clear and transparent; 2 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the color of the solution remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution changed from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0100] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0101] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0102] Example 5
[0103] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0104] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0105] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0106] Take 152.3 mg of reduced glutathione and 2 mL of deionized water, add them into an EP tube and place it in an ultrasonic disperser to fully dissolve and disperse, with a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0107] Take Mn2(CO) 10 4.2 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0108] Take 63 mg of bovine serum albumin and 2 mL of deionized water, and fully dissolve to obtain a bovine serum albumin solution for use;
[0109] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0110] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0111] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0112] Take 278 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the color of the solution remained clear and transparent; 2 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the color of the solution remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution changed from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0113] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0114] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0115] Example 6
[0116] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0117] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0118] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0119] Take 200.5 mg of reduced glutathione and 2.5 mL of deionized water, add them into an EP tube and place them in an ultrasonic disperser to fully dissolve and disperse them at a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0120] Take Mn2(CO) 10 12.48 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0121] Take 126 mg of bovine serum albumin and 4 mL of deionized water, fully dissolve to obtain a bovine serum albumin solution for use;
[0122] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0123] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0124] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0125] Take 275.5 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2.5 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the solution color was still clear and transparent; 4 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the solution color remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution was observed to change from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0126] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0127] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0128] Example 7
[0129] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0130] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0131] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0132] Take 203.1 mg of reduced glutathione and 2.5 mL of deionized water, add them into an EP tube and place them in an ultrasonic disperser to fully dissolve and disperse them at a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0133] Take Mn2(CO) 10 4.2 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0134] Take 126 mg of bovine serum albumin and 4 mL of deionized water, fully dissolve to obtain a bovine serum albumin solution for use;
[0135] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0136] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0137] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0138] Take 275.5 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2.5 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the solution color was still clear and transparent; 4 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the solution color remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution was observed to change from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0139] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0140] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
[0141] Example 8
[0142] Preparation of a diagnostic and therapeutic integrated nanoprobe:
[0143] Take 112g of potassium hydroxide and 1L of deionized water, add them into a beaker and mix thoroughly, transfer the mixture to a volumetric flask, and prepare a potassium hydroxide solution with a concentration of 2mol / L for later use;
[0144] Take 126 mg of tetrachloroauric acid trihydrate and 1 mL of deionized water, add them into the EP tube and mix thoroughly to obtain a tetrachloroauric acid trihydrate solution for use;
[0145] Take 203.1 mg of reduced glutathione and 2.5 mL of deionized water, add them into an EP tube and place them in an ultrasonic disperser to fully dissolve and disperse them at a frequency of 50 KHz and a dispersion time of 10 s to form a clear reduced glutathione solution for use;
[0146] Take Mn2(CO) 10 2.5 mg of compound was fully dissolved in 0.5 mL of DMSO in a dark environment for later use;
[0147] Take 126 mg of bovine serum albumin and 4 mL of deionized water, fully dissolve to obtain a bovine serum albumin solution for use;
[0148] Weigh 5 mg of EDC and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an EDC aqueous solution for later use;
[0149] Weigh 5 mg of NHS and 5 mL of deionized water, add them into the EP tube and mix thoroughly to obtain an NHS aqueous solution for later use;
[0150] Dilute the 3-azidopropylamine solution to 10 mg / mL for later use;
[0151] Take 275.5 mL of deionized water and place it in a three-necked round-bottom beaker; add 1 mL of the previously prepared tetrachloroauric acid trihydrate solution into the deionized water; slowly drop 2.5 mL of reduced glutathione solution into the above mixed solution under vigorous stirring (880 r / min), stir at 880 r / min for 8 min, and the solution gradually changes from golden yellow to clear and transparent; then take the Mn2(CO) dissolved in DMSO 10 0.5 mL of the compound solution was slowly added, and the mixture was stirred at 880 r / min for 8 min, and the solution color was still clear and transparent; 4 mL of the pre-prepared bovine serum albumin solution was slowly added dropwise to the mixed solution under rapid stirring (880 r / min), and the solution color remained unchanged after being stirred for 15 min; 1.3 mL of the pre-prepared 2 mol / L potassium hydroxide solution was taken to adjust the pH of the mixed solution to 11, and during the adjustment process, the mixed solution was observed to change from clear to turbid and then to clear; then, the mixed solution was aerated with CO at a pressure of 1 bar for 15 min for reduction and protection, and slowly stirred at room temperature for 24 h to obtain the bovine serum albumin-encapsulated nanocomposite AM@BSA;
[0152] The brown-red product obtained in the above steps was separated by 10KD ultrafiltration separation tube at 3500 r / min for 10 min, washed with deionized water for 3 times, and freeze-dried to obtain a quantitative bovine serum albumin-coated nanocomposite AM@BSA;
[0153] A mixed solution of 1.116 mL of EDC aqueous solution, 0.99 mL of NHS aqueous solution, and 2 mL of 3-azidopropylamine was prepared and stirred at room temperature for 60 min; 5 mL of 2 mg / mL nanocomplex AM@BSA solution was added to the above mixed solution and stirred in an ice bath for 12 h. The product was separated by a 30KD ultrafiltration separation tube at 3500 r / min for 15 min and washed with deionized water three times to obtain the final response to release CO, gas, and chemical kinetics synergistic inhibition of bone metastasis NIR-II diagnosis and treatment integrated nanoprobe AM@BSAN.
Claims
1. A nanoprobe for integrated diagnosis and treatment, Features: The nanoprobe is Au-Mn 2 (CO) 10 @BSA-N 3 , its structure is evenly distributed and its morphology is spherical; The core of the nanoprobe structure is a gold cluster loaded with carbon monoxide-releasing molecules carbonyl manganese Mn 2 (CO) 10 The formed composite structure uses reduced glutathione as a ligand, and is coated with bovine serum albumin and modified with azide compounds on the outside.
2. The integrated diagnosis and treatment nanoprobe according to claim 1, Features: The hydrated particle size of the nanoprobe is 10-13 nm.
3. A method for preparing the integrated diagnosis and treatment nanoprobe according to claim 1, Features: The probe is based on gold clusters and loaded with Mn 2 (CO) 10 The formed composite structure is used as the core of the nanoprobe, and reduced glutathione is selected as the ligand. Bovine serum albumin is coated on the outside and modified with an azide compound.
4. A method for preparing a diagnosis and treatment integrated nanoprobe according to claim 3, It is characterized in that The preparation method specifically comprises the following steps: S1: adding tetrachloroauric acid trihydrate aqueous solution into deionized water, and then adding reduced glutathione aqueous solution under high-speed stirring to form a transparent aqueous solution of gold clusters protected by glutathione as a ligand; S2: Mn dissolved in dimethyl sulfoxide 2 (CO) 10 Add the compound solution to the solution obtained in step S1 and continue stirring; S3: adding the bovine serum albumin aqueous solution to the solution in step S2 under stirring to obtain a clear mixed solution; S4: adjusting the pH of the solution in step S3 with an aqueous potassium hydroxide solution; S5: CO2 is introduced into the solution obtained in step S4 and the stirring is continued, followed by washing, centrifugation, and freeze-drying to obtain a nanocomplex AM@BSA wrapped by bovine serum albumin; S6: Mix the aqueous solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, the aqueous solution of N-hydroxysuccinimide and the solution of 3-azidopropylamine, and stir, add the aqueous solution of the nanocomplex AM@BSA obtained in step S5, and continue stirring, then centrifuge and wash the product to obtain the integrated diagnosis and treatment nanoprobe.
5. The method for preparing a diagnosis and treatment integrated nanoprobe according to claim 4, Features: In step S1, the concentration of the tetrachloroauric acid trihydrate aqueous solution is 126-131.8 mg / mL, and the amount used is 1 mL; the concentration of the reduced glutathione aqueous solution is 75.15-81.1 mg / mL, and the amount used is 2-2.5 mL; the amount of water used is 275.5-278 mL; the stirring speed is 880 r / min, and the stirring time is 8 min.
6. The method for preparing a diagnosis and treatment integrated nanoprobe according to claim 4, Features: In step S2, Mn 2 (CO) 10 The concentration of the solution was 5-24.96 mg / mL, the dosage was 0.5 mL, the stirring speed was 880 r / min, and the stirring time was 8 min.
7. The method for preparing a diagnosis and treatment integrated nanoprobe according to claim 4, Features: The concentration of the bovine serum albumin aqueous solution in step S3 is 31.5 mg / mL, the dosage is 2-4 mL, and the stirring time is 15 min.
8. The method for preparing a diagnosis and treatment integrated nanoprobe according to claim 4, Features: In step S4, the concentration of the potassium hydroxide aqueous solution is 2 mol / L, and the adjusted pH value is 11; in step S5, the CO ventilation pressure is 1 bar, and the ventilation time is 15 min; the stirring temperature of the reaction mixture is room temperature, and the stirring time is 24 h; the centrifugation uses an ultrafiltration separation tube 10KD, the speed is 3500 r / min, and the time is 10 min.
9. The method for preparing a diagnosis and treatment integrated nanoprobe according to claim 4, Features: In the step S6, the concentration of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride aqueous solution is 1 mg / mL, and the amount is 1.116 mL; the concentration of the N-hydroxysuccinimide aqueous solution is 1 mg / mL, and the amount is 0.99 mL; the concentration of the 3-azidopropylamine solution is 10 mg / mL, and the amount is 2-3 mL; the stirring temperature is room temperature, and the stirring time is 60 min; the concentration of the nanocomposite AM@BSA aqueous solution is 2 mg / mL, and the amount is 5 mL; the nanocomposite AM@BSA aqueous solution is added and the stirring condition is continued in an ice water bath for 12 h; The centrifugal separation was carried out using an ultrafiltration separation tube 30 KD at a speed of 3500 r / min for 15 min.
10. An application of the diagnosis and treatment integrated nanoprobe according to claim 1, Features: Used to prepare integrated diagnostic and therapeutic nanoreagents for bone metastases.
Citation Information
Patent Citations
Glutathione-triggered tumor diagnosis and treatment reagent
CN110404071A
Activatable diagnosis and treatment integrated nanoprobe as well as preparation method and application thereof
CN115252811A
